A rare incidence of cerebral venous thrombosis in a case of immune thrombocytopenia on eltrombopag

Immune Thrombocytopenia (ITP) typically presents with mucocutaneous bleeding. Splenectomy, rituximab, and thrombopoietin receptor agonists (TPO-RAs) are the recommended second-line therapy. Eltrombopag is one of the TPO-RAs used for the treatment of steroid-refractory ITP, with a response rate of 70–80%. Though rare, yet various cases of venous thromboembolism have been reported from clinical trials as well as real-world studies. We present a case of ITP that was refractory to corticosteroid and second-line drugs; however, it responded to eltrombopag. While having a complete response on eltrombopag, the patient developed Cerebral Venous Thrombosis.